Clinical trials for Anal cancer

87 currently recruiting clinical trials
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06128551
Phase 1b Escalade de dose
Locally Advanced Metastatic Metastatic Castration-resistant KRAS G12C 1 2 3 or more
Systemic Treatment-Naive
Institut du cancer de Montpellier (Montpellier), Centre Léon Bérard (Lyon), Hôpital Louis Pradel (Bron ), Institut Bergonié (Bordeaux), Centre Oscar Lambret (Lille) (and 2 more...)
Revolution Medicines, Inc.
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06128551
Phase 1b extension de dose et phase 2 cohortes tumeurs solides naïves d'inhibiteurs de KRAS G12C
Locally Advanced Metastatic Metastatic Castration-resistant KRAS G12C 1 2 3 or more
Systemic Treatment-Naive Targeted therapy
Institut du cancer de Montpellier (Montpellier), Centre Léon Bérard (Lyon), Hôpital Louis Pradel (Bron ), Institut Bergonié (Bordeaux), Centre Oscar Lambret (Lille) (and 2 more...)
Revolution Medicines, Inc.
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT05768139 #2023-000442-41
Cohortes monothérapie (partie 1)
HR Positive Locally Advanced Metastatic PIK3CA 1 2 3 or more
Centre Léon Bérard (Lyon), Gustave Roussy (Villejuif), Institut Bergonié (Bordeaux), IUCT Oncopôle (Toulouse), IUCT Oncopôle (Toulouse)
Eli Lilly et compagnie
Phase 1 / Phase 2 Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06726148 #2024-517281-42-00
Phase I - cancer amplifié CCNE1
Locally Advanced Metastatic Other mutation 1 2 3 or more
Systemic Treatment-Naive
Institut de Cancérologie de l'Ouest - Site de Saint-Herblain (Saint-Herblain), Institut Bergonié (Bordeaux)
Novartis
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06923761 #2023-504845-30-00
Module 1 (Partie A, B, C) et module 2 (parties A et B) Tumeurs solides avancées
Locally Advanced Metastatic 1 2 3 or more
Systemic Treatment-Naive
Centre Eugene Marquis (Rennes), Centre Léon Bérard (Lyon), ICANS - Institut de cancérologie Strasbourg Europe (Strasbourg), IUCT Oncopôle (Toulouse), Gustave Roussy (Villejuif) (and 2 more...)
Grey Wolf Therapeutics
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06669117 #2024-512760-64-00
Partie 1 (Escalade de dose)
Locally Advanced Metastatic Metastatic Castration-resistant MET 1 2 3 or more
Systemic Treatment-Naive
Hôpital Nord de Marseille (Marseille Cedex 20), Gustave Roussy (Villejuif), Centre Hospitalier Universitaire de Toulouse (Toulouse), Institut de Cancérologie de l'Ouest - Site de Saint-Herblain (Saint-Herblain)
Laboratoires Pierre Fabre
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06188702 #2025-521249-25-00
Phase 1 Dose Escalation
Locally Advanced Metastatic MTAP 1 2 3 or more
Systemic Treatment-Naive
Gustave Roussy (Villejuif), CGFL Dijon - Centre Régional De Lutte Contre Le Cancer Georges - François Leclerc (Dijon )
Servier
Phase 1 / Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Bladder / Urinary Tract / Urethral cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06188702 #2025-521249-25-00
Cohort Basket - autres tumeurs
Locally Advanced Metastatic MTAP 1 2 3 or more
Systemic Treatment-Naive
CGFL Dijon - Centre Régional De Lutte Contre Le Cancer Georges - François Leclerc (Dijon ), Gustave Roussy (Villejuif)
Servier
Phase 1 / Phase 2 #NCT05118789
Locally Advanced Metastatic ROS-1 1
Systemic Treatment-Naive
Centre Léon Bérard (Lyon), Gustave Roussy (Villejuif), Centre Hospitalier Universitaire - Site Hôtel Dieu (Nantes), Centre Hospitalier Universitaire de Toulouse (Toulouse)
Nuvalent Inc.
Phase 1 / Phase 2 Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Stomach and esophageal cancer #NCT04585750 #2023-504251-27-00
Locally Advanced Metastatic TP53 1 2 3 or more
KRAS G12C KRAS non G12C Systemic Treatment-Naive
Institut de Cancérologie de Lorraine - Alexis Vautrin (Vandœuvre-lès-Nancy), Centre Hospitalier Universitaire de Nîmes (Nîmes), IUCT Oncopôle (Toulouse), Institut de Cancérologie de l'Ouest - Site de Saint-Herblain (Saint-Herblain), ICANS - Institut de cancérologie Strasbourg Europe (Strasbourg) (and 4 more...)
PMV Pharmaceuticals, Inc